Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10402MR)

This product GTTS-WQ10402MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Autoimmune diseases, Rheumatoid arthritis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ10402MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14680MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ2622MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ14890MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ2866MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-570
GTTS-WQ6668MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ6405MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ6801MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ4383MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-224818
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW